At a glance
ClinicalIndex Comparison RecordN/ACompleted· 672 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-Interventional, Prospective Cohort Study of the Effectiveness, Safety and Utilization of Two Approved Pegylated Interferon-Based Direct Acting Antiviral Triple Therapies in the Management of Genotype 1 Chronic Hepatitis C in Routine Clinical Practice in the USA
In Brief
An observational study for Hepatitis C, Chronic. Completed, enrolled 672 participants across 66 sites in 2 countries.
Detailed Summary
This prospective observational study will evaluate the efficacy and safety of two approved pegylated interferon-based direct acting antiviral triple therapies in patients with chronic hepatitis C genotype 1. Patients receiving pegylated interferon (e.g. Pegasys) and ribavirin plus either telaprevir or boceprivir in accordance with local standard of care and US labeling will be followed for the duration of their treatment and for up to 24 weeks post-treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
CountriesPuerto Rico, United States
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartJan 2012
Primary CompletionMar 2014
TodayJul 2026
First PostedJan 11, 2012
Enrollment StartJan 31, 2012
Primary CompletionMar 31, 2014
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 14.5 years ago